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Abstract
Background: The aim of the study was to compare the two irradiation modes with (FF) and without flattening
filter (FFF) for three different treatment techniques for simultaneous integrated boost radiation therapy of patients
with right sided breast cancer.
Methods: An Elekta Synergy linac with Agility collimating device is used to simulate the treatment of 10 patients.
Six plans were generated in Monaco 5.0 for each patient treating the whole breast and a simultaneous integrated
boost (SIB) volume: intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT) and a
tangential arc VMAT (tVMAT), each with and without flattening filter. Plan quality was assessed considering target
coverage, sparing of the contralateral breast, the lungs, the heart and the normal tissue. All plans were verified by a
2D-ionisation-chamber-array and delivery times were measured and compared. The Wilcoxon test was used for
statistical analysis with a significance level of 0.05.
Results: Significantly best target coverage and homogeneity was achieved using VMAT FFF with V95% = (98.7 ± 0.8) %
and HI = (8.2 ± 0.9) % for the SIB and V95% = (98.3 ± 0.7) % for the PTV, whereas tVMAT showed significantly lowest
doses to the contralateral organs at risk with a Dmean of (0.7 ± 0.1) Gy for the contralateral lung, (1.0 ± 0.2) Gy for the
contralateral breast and (1.4 ± 0.2) Gy for the heart. All plans passed the gamma evaluation with a mean passing rate of
(99.2 ± 0.8) %. Delivery times were significantly reduced for VMAT and tVMAT but increased for IMRT, when FFF was
used. Lowest delivery times were observed for tVMAT FFF with (1:20 ± 0:07) min.
Conclusion: Balancing target coverage, OAR sparing and delivery time, VMAT FFF and tVMAT FFF are considered the
preferable of the investigated treatment options in simultaneous integrated boost irradiation of right sided breast
cancer for the combination of an Elekta Synergy linac with Agility and the treatment planning system Monaco 5.0.
Abbreviations: CI, Conformity index; Dmean, Mean dose of a structure; DVH, Dose volume histogram; Dx, Dose to
volume x of the structure; FF, Flattening filter; FFF, Flattening filter free; HI, Homogeneity index; IMRT, Intensity
modulated radiation therapy; Min, Minutes; MLC, Multi leaf collimator; PIV, Total volume of the 95 % isodose;
PTV, Planning target volume; ROI, Region of interest; TV, Volume of the PTV; tVMAT, Tangential arc VMAT;
VMAT, Volumetric modulated arc therapy; Vx%, Volume covered by x% of the prescription dose
* Correspondence: barbara.dobler@ukr.de
1Department of Radiotherapy, Regensburg University Medical Center,
Regensburg, Germany
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Maier et al. Radiation Oncology  (2016) 11:111 
DOI 10.1186/s13014-016-0687-6
Background
Adjuvant radiation therapy following breast conserving
surgery allows improving local control and overall sur-
vival in early stage breast cancer patients [1]. Treatment
techniques for radiation therapy have been established
ranging from conventional tangential fields over inten-
sity modulated radiation therapy (IMRT) to volumetric
modulated arc therapy (VMAT), and been compared in
various planning studies [2–10]. Cardiac sparing in pa-
tients with left sided breast cancer has been considered
the main advantage of IMRT and VMAT as compared to
tangential fields [2–7, 11]. A few planning studies include
right sided as well as left sided breast cancer [8–10], but
dedicated planning studies for right sided breast cancer
seemed not to be of interest up to now. During the last
years, however, simultaneous integrated boost radiation
therapy superseded sequential boost therapy as the stand-
ard fractionation scheme [12, 13]. In this case, IMRT and
VMAT have shown advantages in target coverage and
sparing of the organs at risk (OAR) as compared to 3D-
CRT techniques [10, 14], thus becoming more important
also for right sided breast cancer.
The latest development in the technology of linear ac-
celerators is the opportunity to irradiate patients without
a flattening filter in the beam path to increase dose rate
and reduce beam-on times as well as out-of-field doses
[15]. Two planning studies have already been published
comparing the two irradiation modes for breast cancer,
both of them dealing with left sided breast cancer [5, 7].
Since dose volume restrictions to the heart might, how-
ever, be limiting the reduction of dose to the other or-
gans at risk to a larger extent in the therapy of left sided
breast cancer, results cannot simply be transferred to
right sided breast cancer cases. Dedicated planning stud-
ies for radiation therapy of right sided breast cancer are
therefore necessary to identify the optimal treatment
technique also for this group of patients.
The aim of the study presented here was to compare
the two irradiation modes with (FF) and without flatten-
ing filter (FFF) for three different treatment techniques
for simultaneous integrated boost radiation therapy of
patients with right sided breast cancer.
Methods
Patients
CT data of 10 patients with right sided breast cancer
were randomly selected from our database for a retro-
spective planning study. The target volumes were delin-
eated by a clinical oncologist according to Dellas et al.
[16]. The PTV includes the whole right mammary gland
without parasternal, axial or supraclavicular lymph
nodes. All patients received a simultaneous boost irradi-
ation to the tumour bed. The volume for the boost
therapy was defined with the help of preoperative
information (results of mammography, ultrasound and
clinical examination) and the surgical report. Moreover
the scar, the presence of surgical clips in the tumour
bed, and changes within the breast tissue following sur-
gery were important information for the definition of
the boost volume. To create the simultaneous integrated
boost planning target volume (SIB) a safety margin was
added to the boost volume. This safety margin was con-
strained to be inside the patient outline.
Target volumes ranged from 454 ccm to 1377 ccm for
the PTV, and from 32 ccm to 172 ccm for the SIB. The
treatment goals were an average dose of 50.4 Gy in 28
fractions of 1.8 Gy in the PTV and 63 Gy in 28 fractions
of 2.25 Gy in the SIB according to Sedlmayer et al. [17].
For the organs at risk (OAR) the following dose volume
tolerances were chosen as clinical goals: The volume of
the ipsilateral lung V20Gy receiving ≥ 20 Gy should be <
15 %, the mean dose < 12 Gy [18]. The volume of the
contralateral lung V5Gy should be restricted to 5 % [19],
the mean dose to 3 Gy [10]. The mean dose to the heart
should be kept below 5 Gy [10, 18]. For the contralateral
breast the mean dose should be < 3 Gy [10].
Linear accelerator and treatment planning system
Treatment planning was performed with Monaco 5.0
(Elekta AB, Stockholm, Sweden) with X-ray Voxel
Monte Carlo (XVMC) dose algorithm for a Synergy lin-
ear accelerator with Agility collimating device (Elekta
AB, Stockholm, Sweden) and 6 MV photons with flat-
tening filter or without, in the following referred to as
FF and FFF beams. The FFF beams were energy-
matched to the FF beams as it is common for Elekta ac-
celerators [20–23]. This means, that the parameters of
the accelerator were tuned for the FFF mode to achieve
the same percentage depth dose at 10 cm depth for a
10 cm × 10 cm field and the same quality index as in FF
mode. The agreement of both parameters was within
1 %. The linac was calibrated such that 100 MU corres-
pond to 1 Gy at the central axis at depth dose maximum
for a 10 cm × 10 cm field with a source surface distance
of 100 cm for both irradiation modes. The multi leaf col-
limator (MLC) consists of 80 leaf pairs of 5 mm width at
isocenter. The transmission was 0.6 % for both irradi-
ation modes. The maximum nominal dose rate is 500
MU/min in FF mode and 1700 MU/min in FFF mode.
Due to limitations in the speed of mechanical move-
ments, the maximum dose rate is, however, not applied
throughout VMAT treatments. Beam profiles, depth
doses and dose output were found to be stable for 4 MU
and larger in both irradiation modes as also reported by
Akino [24]. Verification of the linac model in Monaco 5.0
with XVMC dose calculations of absolute dose, percent-
age depth doses, profiles, and output factors was within
specifications for both FF and FFF. The specifications were
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2 % of calibration dose in low dose gradient areas (high
and low dose) and 3 mm distance to agreement in sharp
dose gradients.
Treatment planning
In total six treatment plans were created for each pa-
tient, using the three different treatment techniques
IMRT, VMAT and tangential arc VMAT (tVMAT) each
with and without flattening filter. The IMRT plans were
realized as step and shoot IMRT and consisted of 10
beams with gantry angles of 55°, 35°, 15°, 355°, 335°,
315°, 285°, 250°, 225°, and 200°. The VMAT plans were
realized with two arcs covering gantry angles from 180°
to 60° clockwise (cw) and counter-clockwise (ccw). For
the tVMAT two partial arcs were used ranging from 60°
to 5° and from 255° to 200° gantry angle ccw similar to
the technique described by Pasler et al. [4]. All plans
were optimized in Monaco 5.0 using identical con-
straints. The optimization in Monaco is based on bio-
logical objective functions rather than on physical dose
volume objectives. Therefore the constraints used for
optimization are not identical to the physical dose vol-
ume tolerances derived from literature and listed in the
section “Patients” and in Table 1 in the column “Goal”.
In Monaco, the constraints to the OAR are prioritized
over the constraints to the targets. Therefore suitable
constraints for optimization were determined creating
plans in FF mode lowering OAR doses as much as pos-
sible without compromising target coverage and homo-
geneity. The identical constraints were then also used
for optimization of the FFF plans. A so called “surface
margin” of 3 mm was used to prevent the optimizer
from adding dose to the surface region to compensate
for the buildup effect. To ensure coverage of the breast a
so called “auto flash margin” of 2 cm was used, which
automatically extends the beam 2 cm beyond the patient
outline. For IMRT the minimal number of monitor units
(MU) per segment was set to 4 due to the determined
stability of the beam for 4 MU and higher. The minimal
segment area was limited to 4 cm2. For VMAT the num-
ber of control points per arc was limited to 120, for
IMRT a straight limitation of control points was not pos-
sible in this version of Monaco. The dose calculation
was performed with a grid size of 3 mm and the statis-
tical uncertainty parameter was set to 1 %. All plans
were normalized to the mean dose in the SIB. In the fol-
lowing the plans are referred to as IMRT FF, IMRT FFF,
VMAT FF, VMAT FFF, tVMAT FF, and tVMAT FFF.
Table 1 Comparison of plan quality
Parameter Goal IMRT FF IMRT FFF VMAT FF VMAT FFF tVMAT FF tVMAT FFF
SIBm5 V95% >95 97.2 ± 1.2 97.5 ± 1.3 98.2 ± 1.0 98.7 ± 0.8 95.5 ± 2.2 95.7 ± 2.0
D98% 59.6 ± 0.4 59.7 ± 0.4 60.0 ± 0.5 60.2 ± 0.4 59.0 ± 0.7 59.1 ± 0.6
D02% 65.6 ± 0.4 65.6 ± 0.2 65.5 ± 0.4 65.3 ± 0.4 66.1 ± 0.4 66.1 ± 0.5
HI 9.6 ± 1.2 9.3 ± 0.9 8.8 ± 1.2 8.2 ± 0.9 11.3 ± 1.4 11.1 ± 1.5
CI >0.7 0.77 ± 0.05 0.78 ± 0.05 0.78 ± 0.05 0.78 ± 0.05 0.75 ± 0.05 0.75 ± 0.05
PTVm5 V95% >95 96.8 ± 2.3 96.8 ± 1.9 97.6 ± 1.5 98.3 ± 0.7 95.2 ± 4.3 94.9 ± 3.8
CI >0.7 0.77 ± 0.05 0.77 ± 0.06 0.77 ± 0.05 0.78 ± 0.05 0.75 ± 0.04 0.76 ± 0.04
PTV (excluding SIB) D98% 46.9 ± 0.7 46.9 ± 0.6 46.9 ± 1.1 47.4 ± 0.6 45.7 ± 2.0 45.5 ± 2.0
D02% 55.2 ± 0.5 55.1 ± 0.3 55.4 ± 0.4 55.4 ± 0.4 56.1 ± 0.7 56.1 ± 0.7
HI 16.4 ± 1.6 16.3 ± 1.1 16.9 ± 2.2 15.8 ± 1.1 20.4 ± 4.5 20.9 ± 4.6
Lung ipsilateral V20Gy <15 13.2 ± 3.8 13.1 ± 3.6 13.1 ± 3.3 13.5 ± 3.3 13.8 ± 3.1 14.1 ± 3.0
Dmean <12 8.7 ± 1.3 8.7 ± 1.3 8.7 ± 1.2 8.9 ± 1.2 8.9 ± 1.0 8.9 ± 1.0
Lung contralateral V5Gy <5 0.2 ± 0.4 0.4 ± 0.4 0.1 ± 0.2 0.3 ± 0.3 0.0 ± 0.0 0.0 ± 0.0
Dmean <3 1.6 ± 0.4 1.7 ± 0.2 1.7 ± 0.2 1.8 ± 0.2 1.0 ± 0.1 0.7 ± 0.1
Breast contralateral Dmean <3 1.8 ± 0.4 1.9 ± 0.4 1.8 ± 0.3 1.8 ± 0.4 1.3 ± 0.2 1.0 ± 0.2
D02% 5.4 ± 1.3 5.6 ± 1.2 4.5 ± 1.0 4.8 ± 1.2 3.2 ± 0.6 2.8 ± 0.8
Heart Dmean <5 2.4 ± 0.5 2.6 ± 0.4 2.7 ± 0.5 2.6 ± 0.5 1.7 ± 0.3 1.4 ± 0.2
D02% 5.0 ± 1.1 5.7 ± 0.9 5.0 ± 1.0 5.1 ± 0.9 3.3 ± 0.5 3.0 ± 0.6
Normal Tissue Dmean 4.4 ± 0.4 4.6 ± 0.3 4.4 ± 0.4 4.4 ± 0.3 3.8 ± 0.3 3.6 ± 0.3
D02% 42.5 ± 1.1 42.2 ± 1.3 41.9 ± 1.7 41.9 ± 1.3 41.9 ± 2.2 41.5 ± 1.9
Mean values and standard deviation of the dose volume parameters for FF and FFF mode averaged over all patients separated by the treatment technique. Dose
values are given in Gy, volumes in % of the structure volume. HI stands for homogeneity index (values are reported in %), CI for conformity index. Bold values
indicate statistically significant superior values in the comparison of FF vs FFF. Bold-italic letters indicate best values in the comparison of all planning techniques
and irradiation modes
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Dosimetry
For verification all 60 plans were transferred to a CT scan
of the MatriXX Evolution™ 2D-ionisation-chamber-array
(IBA Dosimetry, Schwarzenbruck, Germany) set up in
between one 10 cm (bottom) and one 9.7 cm (top) stack
of RW3 slabs (PTW, Freiburg, Germany) for measure-
ment in a coronal plane [25, 26]. Measurements were cor-
rected for angular dependencies and couch attenuation in
the software OmniPro I’mRT v.1.7a (IBA Dosimetry,
Schwarzenbruck, Germany) which is steering the meas-
urement and used for evaluation. Gamma indices as de-
fined by Low et al. [27] were calculated with a dose
tolerance of 3 % of the maximum dose and 3 mm distance
to agreement. Dose calculations are considered acceptable
if at least 95 % of the pixels with a dose value of ≥ 10 % of
the maximum dose have a gamma value ≤ 1 as recom-
mended by the AAPM TG119 [28, 29]. For verification of
the dose calculation in the low dose region a second setup
was used with only 1 cm RW3 buildup on top of the
MatriXX Evolution™. The isocenter was placed such that
the high dose area of the PTV was inside the phantom to
maintain phantom scatter and the dose region corre-
sponding to the medial part of the contralateral breast was
located in the active area of the MatriXX Evolution™. A re-
gion of interest (ROI) was defined in the software Omni-
Pro I’mRT in the low dose area corresponding to the
contralateral breast for evaluation as illustrated in Fig. 1
by the orange rectangle. The size of the rectangle was
about 8 cm in width and the full size of the active area of
the MatriXX in cranio-caudal direction. Dose differences
between measured and calculated doses in the ROI were
calculated and compared for the different techniques.
Efficiency
Delivery times were measured from first beam on to last
beam off to assess the achievable reduction in total de-
livery time. In addition the number of required monitor
units (MU) and control points was compared.
Evaluation
Plan quality was assessed by analysis of the dose volume
histogram (DVH) with respect to target coverage, dose
homogeneity and conformity, dose to the organs at risk
and normal tissue as described in the treatment goals.
For evaluation the PTV and SIB were cropped by 5 mm
from the external contour (PTVm5 and SIBm5) as it is
common to account for the buildup effect [5, 7]. Target
coverage was represented by the volume of PTVm5 and
SIBm5 covered by 95 % of the prescription dose (V95%).
The homogeneity index was defined as HI := (D2% -
D98%)/D50% according to ICRU 83 [30] and reported in
percent, the conformity index according to Paddick et al.
[31] as CI := V95%
2 / (TV ⋅ PIV). Here TV means the vol-
ume of the respective target, PIV the total volume
covered by 95 % of the prescription dose in the respect-
ive target. Minimum and maximum doses were repre-
sented by the dose to 98 and 2 % of the volume (D98%
and D02%) according to ICRU recommendations [30].
The homogeneity index, D98% and D02% were recorded
for SIBm5 and for PTVm5 excluding the SIB extended
by a 5 mm margin, to exclude the high dose region of
the SIB from the analysis of the PTV. The DVH parame-
ters recorded for the OAR were Dmean for all OAR and
V20Gy for the ipsilateral lung, V5Gy for the contralateral
lung, and D02% for the contralateral breast, the heart and
the normal tissue.
The Wilcoxon test implemented in IBM SPSS® Statistics
23.0 (IBM Corporation) was used for statistical analysis
with a significance level of 0.05. Statistically significant
differences are reported in the text.
Results
Plan quality
Details about DVH parameters averaged over all patients
are given in Table 1. A comparison of dose distributions
and corresponding dose volume histograms for FF ver-
sus FFF mode for all treatment techniques is shown in
Figs. 2 and 3 for a case with medium sized targets. The
results listed in Table 1 show that FFF led to significantly
superior results in plan quality when VMAT or tVMAT
were used as treatment technique: VMAT FFF improved
target coverage and homogeneity significantly keeping
OAR doses comparable to VMAT FF. tVMAT FFF re-
duced OAR doses significantly without compromising tar-
get coverage and homogeneity as compared to tVMAT
FF. For IMRT, on the contrary, FF showed better results,
since only one significant difference was in favour of FFF
as compared to three in favour of FF. Differences between
the irradiation modes were, however, in general small even
though statistically significant, and OAR doses were
mostly below the goal in both treatment modes.
For comparison of the planning techniques, the statisti-
cally superior plan of each technique was chosen, i.e. IMRT
FF, VMAT FFF and tVMAT FFF. VMAT FFF showed over
all best target coverage and homogeneity with similar doses
to the OAR and the normal tissue as compared to IMRT
FF. tVMAT FFF showed lowest doses to the contralateral
OAR at the cost of reduced target coverage and homogen-
eity as compared to both VMAT FFF and IMRT FF. The
goal of V95% > 95 % in the SIBm5 was achieved in only
50 % of the cases for tVMAT FFF as compared to 100 % of
the cases for VMAT FFF. Figure 4 shows a comparison of
the dose volume histograms of the superior plan of each
treatment techniques for the patient of Figs. 2 and 3.
Dosimetry
All 60 plans passed the gamma evaluation in the measure-
ment setup 1 with a mean passing rate of (99.2 ± 0.7) %
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for FF and (99.1 ± 0.8) % for FFF plans. Passing rates
were > 97.0 % in all cases i.e. well above the tolerance of
95 %. Average doses in the low dose ROI in setup 2 were
(20.1 ± 7.8) cGy (measured) and (19.7 ± 7.7) cGy (calcu-
lated). The verification of the dose calculation in this low
dose region showed large differences between the treat-
ment techniques: High agreement between calculations
and measurements could be observed for VMAT and
tVMAT plans both in FF and FFF mode, with dose
deviations of (0.3 ± 2.0) %, (0.2 ± 1.6) %, (0.1 ± 2.1) % and
(0.6 ± 1.8) % of the average dose in the ROI for VMAT FF,
VMAT FFF, tVMAT FF and tVMAT FFF respectively.
This corresponds to dose deviations of well below ±
1.0 cGy. For IMRT plans, however, dose deviations were
significantly higher with (−6.0 ± 2.0) % in FF mode and
(−9.3 ± 3.0) % in FFF mode, but still in the range of 1 % of
the prescription dose. Negative signs mean an underesti-
mation of dose in the dose calculation.
Fig. 1 Measurement setup for verification of the low dose. Transversal (top) and coronal (bottom) CT slice of the phantom used for verification of
the dose in the low dose region. The isocenter was placed such that the high dose area of the PTV (red) was inside the phantom to maintain
phantom scatter and the dose region corresponding to the medial part of the contralateral breast (green) was located in the active area of the
MatriXX Evolution. Isodoses are given in Gy. The orange box shows the ROI used for evaluation of the low dose region
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Efficiency
Treatment times were significantly reduced by 7 % for
VMAT and 32 % for tVMAT in FFF mode as compared
to FF. IMRT FFF, on the contrary, showed on average
8 % longer delivery times than IMRT FF, differences
were, however, not statistically significant in this case.
Comparison over all treatment techniques showed low-
est treatment times for tVMAT FFF, with a reduction by
86 % as compared to IMRT FF and by 46 % as compared
to VMAT FFF. Details are listed in Table 2.
Discussion
The aim of this study was to investigate the potential of
the flattening filter free (FFF) mode of a linear acceler-
ator for three different treatment techniques for patients
with right sided breast cancer. The results of the study
show, that FFF led to significantly superior results with
regard to plan quality, when VMAT or tVMAT were
used as planning technique, whereas the opposite was
the case for IMRT. Differences in plan quality were,
however, in general small and the clinical relevance of
the differences remains to be shown. The constraints
used for optimization were derived from iterative treat-
ment planning in FF mode and used for optimization in
FFF mode without adaptation. This approach was
chosen for reasons of comparability in order to not bias
the results by the use of different constraints. It might
be possible to further improve plan quality in FFF mode
by adjusting the constraints for the optimization in FFF
mode. This is, however, beyond the scope of this study.
Comparison of all treatment techniques and irradi-
ation modes showed significantly best target coverage
and homogeneity for VMAT FFF and lowest doses to
the contralateral OAR and normal tissue for tVMAT
FFF. This has been confirmed by measurements which
showed high agreement between measurements and cal-
culations in the low dose region for VMAT and tVMAT
as well as in the high dose area corresponding to the tar-
get volumes for all plans. No significant differences
could be observed in dose calculation accuracy between
the two irradiation modes FF and FFF neither in the
high nor in the low dose region. Gamma passing rates
were high (above 97 %) for each individual plan inde-
pendently of the treatment technique and irradiation
mode. Dose deviations in the low dose region were sig-
nificantly higher for IMRT than for VMAT and tVMAT
in both irradiation modes, but still in the range of 1 % of
the prescription dose, which is excellent considering the
recommendations of ESTRO for the verification of simple
open fields with tolerances of 3 % of the central axis dose
or 30 % of the local dose in the low dose region [32]. For
verification of complete IMRT plans, a confidence limit of
4 % is recommended [33]. With respect to dose calcula-
tion accuracy VMATand tVMATare therefore considered
Fig. 2 Comparison of dose distributions of FF versus FFF for all techniques. Comparison of dose distributions for all treatment techniques and
irradiation modes in one transversal slice for a sample case. The PTV is delineated in red, SIB bright blue, ipsilateral lung magenta, contralateral lung
pink, heart brown, contralateral breast green, spinal cord blue and spinal canal green. Isodoses are given in percent of the prescription dose to the SIB,
i.e. 63 Gy. The orange band shows 95 % of the prescription dose to the SIB, the bright blue the 95 % of the prescription dose to the PTV
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Fig. 3 Comparison of dose volume histograms of FF versus FFF for all techniques. Comparison of dose volume histograms for the case of Fig. 2.
Solid lines show DVH of the FF plan, dotted lines of the corresponding FFF plan. PTVm5 is drawn in red, SIBm5 bright blue, ipsilateral lung
magenta, contralateral lung pink, heart brown, contralateral breast green, normal tissue beige. The spinal cord and spinal canal are not shown for
the sake of clarity
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the preferred treatment techniques independently on the
irradiation mode.
The number of MU and control points was signifi-
cantly higher in FFF irradiation mode, with an increase
by 17 % for tVMAT, 19 % for VMAT and 26 % for IMRT
plans. The significantly highest number of MU was ob-
served for VMAT FFF. The increase in MU can be ex-
plained by the fact that the linac is calibrated such that
100 MU correspond to 1 Gy under reference conditions
on the central beam axis for both FF and FFF. Due to
the shape of the dose profile, the dose is lower outside
the central axis for FFF beams. Therefore additional MU
delivered in smaller off axis segments are required to
achieve the same dose away from the central beam in
FFF mode. Concerns had been raised that an increase of
MU might mitigate the potential advantages of FFF with
respect to treatment time and MLC transmission leading
to potentially higher OAR and normal tissue doses. The
results of our study showed that for VMAT and tVMAT
treatment times were significantly reduced by 7 % and
32 % and doses to the OAR were comparable for VMAT
and even significantly reduced for tVMAT despite of
significantly increased MU in FFF mode. Due to the ex-
cellent agreement between dose calculations and mea-
surements for VMAT and tVMAT in the low as well as
in the high dose region, the results of the dose volume
analysis are considered reliable. For IMRT, longer treat-
ment times and a significant increase in OAR doses were
observed in the DVH analysis, normal tissue dose was at
the same time significantly reduced. The results of the
DVH analysis are, however, somewhat less reliable for
IMRT than for VMAT and tVMAT due to the observed
uncertainty in dose calculation in the low dose region.
The difference in the influence of irradiation mode on
treatment time can be explained by the fact that for step
and shoot IMRT delivery times increase with the number
of control points due to the interruption of irradiation
during movement of the MLC. For VMAT techniques the
number of control points does not affect the treatment
time, since the beam stays on during MLC movement.
The number of MU required in FFF plans increased by a
factor of 1.2 whereas dose rates delivered in FFF mode
Fig. 4 Comparison of dose volume histograms of different treatment techniques. Comparison of dose volume histograms of the different
treatment techniques for the case of Fig. 2. For the sake of clarity only the superior plan is shown for each technique, i.e. IMRT FF, VMAT FFF and
tVMAT FFF. PTVm5 is drawn in red, SIBm5 bright blue, ipsilateral lung magenta, contralateral lung pink, heart brown, contralateral breast green,
normal tissue beige
Table 2 Comparison of plan delivery
Plan Time [min:sec] MU Control points
IMRT FF 09:29 ± 1:25 630 ± 114a 188 ± 31a
IMRT FFF 10:13 ± 1:30 792 ± 128 228 ± 39
VMAT FF 2:38 ± 0:17 713 ± 77a 162 ± 10a
VMAT FFF 2:27 ± 0:14 852 ± 105 181 ± 7
tVMAT FF 1:58 ± 0:14 651 ± 124a 53 ± 2
tVMAT FFF 1:20 ± 0:07 763 ± 96 52 ± 2
Mean values and standard deviation of delivery time, monitor units and
control points for FF and FFF mode averaged over all patients separated by
the treatment technique. Bold values indicate statistically significant superior
values in the comparison of FF vs FFF. Bold-italic letters indicate best values in
the comparison of all planning techniques and irradiation modes. aindicates
statistical significance in the comparison of FF vs FFF without judgement, since
the number of monitor units and the number of control points are no
measures of quality
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increased by up to a factor of 3.4, leading to shorter treat-
ment times for FFF in VMAT and tVMAT techniques.
The maximum dose rate is, however, not applied through-
out the whole treatment, due to limitations in the speed of
mechanical movements therefore the ratio of treatment
time in FFF mode to treatment time in FF mode is in gen-
eral larger than 1.2: 3.4. In simultaneous integrated boost
irradiation using IMRT, VMAT or tVMAT dose conform-
ity is higher as compared to conventional tangential field
techniques for whole breast treatment. Therefore reduc-
tion of intrafractional movement becomes more import-
ant, to avoid shifts of the dose distribution relative to the
target due to systematic drifts in patient position [34].
Wiant et al. showed in their study of intrafraction motion
of breast cancer patients, “that the patients tend to drift
further away from their initial position and they tend to
have more short-term random motion as time in the treat-
ment position increases” [35]. The authors observed a lin-
ear increase of the mean shift with time during the first
5 min of a fraction. The reduction of the total treatment
time observed for tVMAT FFF is therefore corresponding
to a reduction of the mean shift by 32 % as compared to
tVMAT FF and 46 % as compared to VMAT FFF. With
respect to treatment time and reduction of shifts of the
dose distributions relative to the target, tVMAT FFF is
therefore considered the preferable treatment option.
An investigation of plan robustness against intrafrac-
tional breathing movement as a function of treatment
technique was, however, beyond the scope of the study.
It is therefore advised to use any form of motion con-
trol in combination with volume imaging to reduce un-
certainties due to breathing.
Balancing target coverage, OAR sparing, agreement of
dose calculations and measurements, and delivery time,
VMAT FFF and tVMAT FFF are considered the preferred
treatment options for SIB radiation therapy of right sided
breast cancer in this study. Due to the relatively large stand-
ard deviations especially in the target coverage for tVMAT
plans and in the V20Gy of the ispilateral lung, the clinical de-
cision is depending on the individual patient’s plan.
Two planning studies have been published comparing
the two irradiation modes for left sided breast cancer,
one of them dealing with whole breast irradiation [5],
the other with SIB treatment [7]. Spruijt et al. [7] per-
formed a planning study for SIB treatment of left sided
breast cancer comparing FF and FFF for different static
field and IMRT techniques planned with Eclipse treat-
ment planning system for a Varian True Beam Linac.
They found comparable plan quality and lower delivery
times when FFF beams were used. For verification of the
dose calculation one phantom case was created for out-
of-field dose measurements 0.3 to 3.1 cm from the field
edge. They found an average reduction in out-of-field
dose of 10 %. Comparison to dose calculations in this
region showed, however, an underestimation by the
treatment planning system Eclipse of 26 % to 85 % as
compared to measurements. Because of the uncertainties
in the dose calculation the authors abandoned evalu-
ation of dose volume parameters of the contralateral
breast and lung in their planning study. The agreement
between calculations and measurements is substantially
higher in our study with (0.1 ± 2.1) % to (−9.3 ± 3.0) %
dose deviation in the low dose region of around 20 cGy
depending on the treatment technique. A comparison of
the plan quality achieved in their study to our results is
therefore not possible.
Koivumaki et al. [5] compared FF and FFF irradiation
for tVMAT and tangential IMRT for whole breast irradi-
ation of left sided breast cancer in a hypofractionated
scheme of 15 × 2.67 Gy. Treatment planning was con-
ducted in an earlier version of Monaco v3.0 for an Elekta
Infinity linac. The authors found a significant reduction
in beam-on time when FFF was used at comparable plan
quality for tVMAT and degraded plan quality for the
tangential IMRT plans. The IMRT and VMAT tech-
niques used in their study differ from the techniques
presented here, but the effect that FFF seems beneficial
for VMAT but not for IMRT treatments can be ob-
served in both studies. Comparing the results of both
studies in plan quality, the differences in total dose of
40 Gy versus 50.4 Gy and 63 Gy have to be taken into
account. Whereas mean doses to the contralateral breast
and lung are similar for the tVMAT plans in both stud-
ies, the mean and maximum dose to the heart and V20Gy
and the Dmean of ipsilateral lung are lower in the study
presented here. The same trend could be observed in
comparison to the results of Pasler et al. [4] who com-
pared tVMAT to VMAT for left sided breast cancer. For
the dose to the heart, differences are expected due to the
location of the heart. The differences in the ipsilateral
lung might be explained by the fact that dose volume re-
strictions to the heart are limiting the reduction of dose to
the ipsilateral lung to a larger extent in the therapy of left
sided breast cancer than for right sided breast cancer.
Conclusions
The use of FFF allowed creating acceptable treatment plan
quality for the combination of an Elekta Synergy linac
with Agility and the treatment planning system Monaco
5.0 in simultaneous integrated boost irradiation of right
sided breast cancer in all three treatment techniques in-
vestigated in this study. FFF led to superior results when
VMAT or tVMAT was used as treatment technique,
whereas for IMRT results were superior in FF mode. Bal-
ancing target coverage, OAR sparing, agreement of dose
calculations and measurements, and delivery time, VMAT
FFF and tVMAT FFF are considered the preferable of the
investigated treatment options.
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